News | May 21, 2012

NIH $2.6 Million Grant Used to Study Imaging Prostate Cancer Without Biopsy

May 21, 2012 — The Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University in Pennsylvania has received a five-year, $2.6 million grant from the National Institutes of Health (NIH). The grant will support investigations of a potentially revolutionary method that can stage prostate cancers and detect recurrent disease more accurately, significantly reducing the number of confirmation biopsies; such biopsies can be invasive, costly and often lead to false-positive readings.

The new technique involves the use of a positron emission tomography (PET) scan and a novel imaging agent. The study is being led by Mathew Thakur, Ph.D., professor of radiology at Jefferson Medical College of Thomas Jefferson University and the director of the Laboratories of Radiopharmaceutical Research and Molecular Imaging.

Prostate specific antigen (PSA) measurements, ultrasonography and magnetic resonance imaging (MRI) remain standard tools for diagnosis and management of prostate cancer; however, each requires an invasive biopsy for histologic confirmation. Biopsies are associated with morbidity and high costs, and more than 65 percent of the 1.5 million biopsies performed each year in the United States show benign pathology, indicating a high false-positive rate for these standard diagnostic tools.

These limitations, the researchers say, demonstrate a dire need for noninvasive methods that can accurately stage prostate cancer, detect recurrent disease and image metastatic lesions with improved reliability.

Thakur and his colleagues are studying Cu-64 peptide biomolecules to evaluate prostate cancer tumors via PET imaging. These agents detect prostate cancer by finding a biomarker called VPAC1, which is over-expressed as the tumor develops.

“The challenge has been to develop an imaging agent that will target a specific, fingerprint biomarker that visualizes prostate cancer early and reliably,” said Thakur, who is also a member of Jefferson’s Kimmel Cancer Center.

Previous studies with Cu-64 peptides from Thakur yielded promising results in stratifying breast cancer. A pre-clinical study published in the Journal of Nuclear Medicine in late 2009 found that 64Cu-TP3805 detected tumors over-expressing the VPAC1 oncogene more accurately in mice than 18F-FDG, a commonly used agent for imaging tumors.

With this NIH grant, the researchers will test the hypothesis in both mice and humans. They will evaluate two Cu-64 peptides specific for VPAC1 in mice and perform a feasibility study in 25 pre-operative prostate cancer patients, using the best-suited Cu-64 peptide determined from the mouse studies.

“This noninvasive method could significantly contribute to the management of prostate cancer,” said Thakur. “It would result in a reduction of unnecessary biopsy procedures and under-treatment or over-treatment that yield minimal benefits, incontinence or impotence.”

Other researchers include Ethan Halpern, M.D., Charles Intenzo, M.D., and Sung Kim, M.D., of the department of radiology; Edouard Trabulsi, M.D., of the department of urology; and Eric Wickstrom, Ph.D., of the department of biochemistry and molecular biology. The team will partner with NuView, a molecular imaging technology firm, on the study.

For more information: www.kimmelcancercenter.org

Related Content

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
PET Tracer Measures Damage From Multiple Sclerosis in Mouse Models
News | PET Imaging | January 24, 2018
January 24, 2018 — The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallma
Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Overlay Init